BGB-A317-LBL-007-201

• Participant must have measurable disease as defined per RECIST version 1.1
• Has a histologically confirmed colorectal adenocarcinoma with metastatic or unresectable disease (Stage IV as defined by American Joint Committee on Cancer [AJCC] 8th edition)
• No prior systemic therapy for colorectal cancer (CRC) in the metastatic setting except for the induction treatment of first-line therapy. Note: Local regional treatment performed during induction systemic treatment is allowed
• Participants who have completed the first-line induction treatment, with an overall response of stable disease or better

• Participants whose disease has become resectable at the investigator’s discretion during or after induction treatment are not eligible
• Induction treatment initiated less than 6 months from completion of any prior neoadjuvant or adjuvant chemotherapy or radiotherapy
• Participants who have been treated with anti-epidermal growth factor receptor (EGFR) antibody in the induction treatment
• Any prior therapy targeting T-cell stimulation or checkpoint pathways
• Participants with documented B-raf proto-oncogene, serine/threonine kinase (BRAF) mutations by local assessments
• Have locally or centrally confirmed microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR) method or deficient mismatch repair (dMMR) immunohistochemistry (IHC). Local result is recommended and acceptable for enrollment. Participants without local testing results are required to have a central laboratory assessment. Note: CRC patients with tumors without mismatch repair (MMR) deficiency or MSI-H status are categorized as pMMR or microsatellite stable (MSS)

View more trial information